Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 inhibitor safety labels

Executive Summary

FDA issues "approvable" letter April 6 for Merck's Vioxx (rofecoxib) for the inclusion of updated gastrointestinal safety data in labeling. Pharmacia/Pfizer's Celebrex (celecoxib) receives "approvable" letter April 12. FDA's Arthritis Advisory Committee recommended Feb. 7-8 that Vioxx and Celebrex could incorporate GI safety data in product labels (1"The Pink Sheet" Feb. 19, p. 11)

You may also be interested in...



Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study

Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.

COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says

The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.

Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study

Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel